Scripps Florida Logo

Welcome to the Rader lab

We pursue both antibody target and drug discovery strategies toward more specific and more potent treatment options for cancer patients. Our target discovery efforts are aimed at identifying new cell surface antigens suitable for monoclonal antibody (mAb) therapy of cancer. Our drug discovery efforts have the objective to develop and utilize antibody display, antibody engineering, and antibody conjugation methods for improving the potency of mAbs. A particular focus in the Rader lab is devoted to antibody technologies at the interface of biology and chemistry, including the generation of molecularly defined antibody-drug conjugates and chemically programmed mAbs and bispecific antibodies. Collectively, these efforts have unveiled several new candidate targets, created a panel of new mAbs, and led to a diverse assortment of new and refined antibody technologies with broad utility for cancer therapy.

Picture: This perspective of the Angel of the West points at our Fab-ulous research at Scripps Florida :-) Several of our antibody drug and target discovery technologies are built on the antibody molecule’s Fab region.



Christoph Rader, Ph.D., Professor, Department of Immunology and Microbiology, The Scripps Research Institute, 130 Scripps Way #2C1, Jupiter, FL 33458, USA; phone (561) 228-2053;

Candice Morrow, Academic Assistant II; phone (561) 228-3249;